Epigenetic alterations and their clinical implications in esophageal squamous cell carcinoma

General Thoracic and Cardiovascular Surgery

Volumn 61, Issue 5, 2013, Pages 262-269

  Toh, Yasushi ^a   Egashira, Akinori ^a   Yamamoto, Manabu ^a  

^a NATIONAL KYUSHU CANCER CENTER   (Japan)

Author keywords

Clinical implications; DNA methylation; Epigenetics; Esophageal squamous cell carcinoma; Histone modification; MicroRNA

Indexed keywords

HISTONE DEACETYLASE 1; HISTONE H3; HISTONE H4; MICRORNA; MICRORNA 100; MICRORNA 140; MICRORNA 150; MICRORNA 151; MICRORNA 205; MICRORNA 21; MICRORNA 25; MICRORNA 29C; MICRORNA 375; MICRORNA 424; MICRORNA 99A; UNCLASSIFIED DRUG;

CHROMATIN ASSEMBLY AND DISASSEMBLY; DEACETYLATION; DNA METHYLATION; EPIGENETICS; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; GENE CONTROL; GENE MUTATION; GENE SILENCING; GENE TARGETING; HISTONE ACETYLATION; HISTONE METHYLATION; HUMAN; MOLECULAR PATHOLOGY; PROMOTER REGION; REVIEW; TUMOR SUPPRESSOR GENE;

ACETYLATION; CARCINOMA, SQUAMOUS CELL; DNA METHYLATION; EPIGENESIS, GENETIC; ESOPHAGEAL NEOPLASMS; GENE EXPRESSION; HISTONES; HUMANS; MICRORNAS; PROTEIN PROCESSING, POST-TRANSLATIONAL; TUMOR MARKERS, BIOLOGICAL;

EID: 84877873177     PISSN: 18636705     EISSN: 18636713     Source Type: Journal    
DOI: 10.1007/s11748-013-0235-3     Document Type: Review

References (60)

1. Shibata A, Matsuda T, Ajiki W, Sobue T. Trend in incidence of adenocarcinoma of the esophagus in Japan, 1993-2001. Jpn J Clin Oncol. 2008;38:464-8.
2. Enzinger PC, Mayer RJ. Esophageal cancer. N Engl J Med. 2003;349:2241-52.
3. Holmes RS, Vaughan TL. Epidemiology and pathogenesis of esophageal cancer. Semin Radiat Oncol. 2007;17:2-9.
4. Toh Y, Oki E, Ohgaki K, Sakamoto Y, Ito S, Egashira A, et al. Alcohol drinking, cigarette smoking, and the development of squamous cell carcinoma of the esophagus: molecular mechanisms of carcinogenesis. Int J Clin Oncol. 2010;15:135-44.
5. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144:646-74.
6. You JS, Jones PA. Cancer genetics and epigenetics: two sides of the same coin? Cancer Cell. 2012;22:9-20.
7. Sawan C, Vaissiere T, Murr R, Herceg Z. Epigenetic drivers and genetic passengers on the road to cancer. Mutat Res. 2008;642:1-13.
8. Kelly TK, De Carvalho DD, Jones PA. Epigenetic modifications as therapeutic targets. Nat Biotechnol. 2010;28:1069-78.
9. Miremadi A, Oestergaard MZ, Pharoah PD, Caldas C. Cancer genetics of epigenetic genes. Hum Mol Genet. 2007;16(Spec No 1):R28-49.
10. Zhao R, Casson AG. Epigenetic aberrations and targeted epigenetic therapy of esophageal cancer. Curr Cancer Drug Targets. 2008;8:509-21.
11. Li JS, Ying JM, Wang XW, Wang ZH, Tao Q, Li LL. Promoter methylation of tumor suppressor genes in esophageal squamous cell carcinoma. Chin J Cancer. 2013;3:3-11.
12. Zhang XM, Guo MZ. The value of epigenetic markers in esophageal cancer. Front Med China. 2010;4:378-84.
13. Baba Y, Watanabe M, Baba H. A review of the alterations in DNA methylation in esophageal squamous cell carcinoma. Surg Today. 2013 (Epub ahead of print).
14. Herceg Z, Ushijima T. Introduction: epigenetics and cancer. Adv Genet. 2010;70:1-23.
15. Baylin SB, Jones PA. A decade of exploring the cancer epigenome - biological and translational implications. Nat Rev Cancer. 2011;11:726-34.
16. Megee PC, Morgan BA, Smith MM. Histone H4 and the maintenance of genome integrity. Genes Dev. 1995;9:1716-27.
17. Dawson MA, Kouzarides T. Cancer epigenetics: from mechanism to therapy. Cell. 2012;150:12-27.
18. Vaissiere T, Sawan C, Herceg Z. Epigenetic interplay between histone modifications and DNA methylation in gene silencing. Mutat Res. 2008;659:40-8.
19. Tzao C, Tung HJ, Jin JS, Sun GH, Hsu HS, Chen BH, et al. Prognostic significance of global histone modifications in resected squamous cell carcinoma of the esophagus. Mod Pathol. 2009;22:252-60.
20. Kondo Y, Shen L, Cheng AS, Ahmed S, Boumber Y, Charo C, et al. Gene silencing in cancer by histone H3 lysine 27 trimethylation independent of promoter DNA methylation. Nat Genet. 2008;40:741-50.
21. Toh Y, Yamamoto M, Endo K, Ikeda Y, Baba H, Kohnoe S, et al. Histone H4 acetylation and histone deacetylase 1 expression in esophageal squamous cell carcinoma. Oncol Rep. 2003;10:333-8.
22. Toh Y, Ohga T, Endo K, Adachi E, Kusumoto H, Haraguchi M, et al. Expression of the metastasis-associated MTA1 protein and its relationship to deacetylation of the histone H4 in esophageal squamous cell carcinomas. Int J Cancer. 2004;110:362-7.
23. Toh Y, Pencil SD, Nicolson GL. A novel candidate metastasis-associated gene, MTA1, differentially expressed in highly metastatic mammary adenocarcinoma cell lines. cDNA cloning, expression, and protein analyses. J Biol Chem. 1994;269:22958-63.
24. Toh Y, Oki E, Oda S, Tokunaga E, Ohno S, Maehara Y, et al. Overexpression of the MTA1 gene in gastrointestinal carcinomas: correlation with invasion and metastasis. Int J Cancer. 1997;74:459-63.
25. Toh Y, Nicolson GL. The role of the MTA family and their encoded proteins in human cancers: molecular functions and clinical implications. Clin Exp Metastasis. 2009;26:215-27.
26. Tzao C, Sun GH, Tung HJ, Hsu HS, Hsu WH, Wang YC, et al. Reduced acetylated histone H4 is associated with promoter methylation of the fragile histidine triad gene in resected esophageal squamous cell carcinoma. Ann Thorac Surg. 2006;82:396-401.
27. Soejima H, Nakagawachi T, Zhao W, Higashimoto K, Urano T, Matsukura S, et al. Silencing of imprinted CDKN1C gene expression is associated with loss of CpG and histone H3 lysine 9 methylation at DMR-LIT1 in esophageal cancer. Oncogene. 2004;23:4380-8.
28. Goel A, Boland CR. Epigenetics of colorectal cancer. Gastroenterology. 2012;143:1442-60.
29. Garzon R, Calin GA, Croce CM. MicroRNAs in cancer. Annu Rev Med. 2009;60:167-79.
30. Lewis BP, Burge CB, Bartel DP. Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell. 2005;120:15-20.
31. Guo Y, Chen Z, Zhang L, Zhou F, Shi S, Feng X, et al. Distinctive microRNA profiles relating to patient survival in esophageal squamous cell carcinoma. Cancer Res. 2008;68:26-33.
32. Matsushima K, Isomoto H, Kohno S, Nakao K. MicroRNAs and esophageal squamous cell carcinoma. Digestion. 2010;82:138-44.
33. Kurashige J, Kamohara H, Watanabe M, Tanaka Y, Kinoshita K, Saito S, et al. Serum microRNA-21 is a novel biomarker in patients with esophageal squamous cell carcinoma. J Surg Oncol. 2012;106:188-92.
34. Hiyoshi Y, Kamohara H, Karashima R, Sato N, Imamura Y, Nagai Y, et al. MicroRNA-21 regulates the proliferation and invasion in esophageal squamous cell carcinoma. Clin Cancer Res. 2009;15:1915-22.
35. Mori Y, Ishiguro H, Kuwabara Y, Kimura M, Mitsui A, Ogawa R, et al. MicroRNA-21 induces cell proliferation and invasion in esophageal squamous cell carcinoma. Mol Med Rep. 2009;2:235-9.
36. Ma WJ, Lv GD, Tuersun A, Liu Q, Liu H, Zheng ST, et al. Role of microRNA-21 and effect on PTEN in Kazakh's esophageal squamous cell carcinoma. Mol Biol Rep. 2011;38:3253-60.
37. Kinoshita T, Hanazawa T, Nohata N, Okamoto Y, Seki N. The functional significance of microRNA-375 in human squamous cell carcinoma: aberrant expression and effects on cancer pathways. J Hum Genet. 2012;57:556-63.
38. Kong KL, Kwong DL, Chan TH, Law SY, Chen L, Li Y, et al. MicroRNA-375 inhibits tumour growth and metastasis in oesophageal squamous cell carcinoma through repressing insulin-like growth factor 1 receptor. Gut. 2012;61:33-42.
39. Matsushima K, Isomoto H, Yamaguchi N, Inoue N, Machida H, Nakayama T, et al. MiRNA-205 modulates cellular invasion and migration via regulating zinc finger E-box binding homeobox 2 expression in esophageal squamous cell carcinoma cells. J Transl Med. 2011;9:30.
40. Yokobori T, Suzuki S, Tanaka N, Inose T, Sohda M, Sano A, et al. MiR-150 is associated with poor prognosis in esophageal squamous cell carcinoma via targeting the EMT inducer ZEB1. Cancer Sci. 2012;104:48-54.
41. Xu X, Chen Z, Zhao X, Wang J, Ding D, Wang Z, et al. MicroRNA-25 promotes cell migration and invasion in esophageal squamous cell carcinoma. Biochem Biophys Res Commun. 2012;421:640-5.
42. Vallbohmer D, Brabender J, Metzger R, Holscher AH. Genetics in the pathogenesis of esophageal cancer: possible predictive and prognostic factors. J Gastrointest Surg. 2010;14(Suppl 1):S75-80.
43. Kaz AM, Grady WM. Epigenetic biomarkers in esophageal cancer. Cancer Lett. 2012 (Epub ahead of print).
44. Guo M, Ren J, Brock MV, Herman JG, Carraway HE. Promoter methylation of HIN-1 in the progression to esophageal squamous cancer. Epigenetics. 2008;3:336-41.
45. Adams L, Roth MJ, Abnet CC, Dawsey SP, Qiao YL, Wang GQ, et al. Promoter methylation in cytology specimens as an early detection marker for esophageal squamous dysplasia and early esophageal squamous cell carcinoma. Cancer Prev Res (Phila). 2008;1:357-61.
46. Hibi K, Taguchi M, Nakayama H, Takase T, Kasai Y, Ito K, et al. Molecular detection of p16 promoter methylation in the serum of patients with esophageal squamous cell carcinoma. Clin Cancer Res. 2001;7:3135-8.
47. Li B, Wang B, Niu LJ, Jiang L, Qiu CC. Hypermethylation of multiple tumor-related genes associated with DNMT3b up-regulation served as a biomarker for early diagnosis of esophageal squamous cell carcinoma. Epigenetics. 2011;6:307-16.
48. Ling Y, Huang G, Fan L, Wei L, Zhu J, Liu Y, et al. CpG island methylator phenotype of cell-cycle regulators associated with TNM stage and poor prognosis in patients with oesophageal squamous cell carcinoma. J Clin Pathol. 2011;64:246-51.
49. Ling ZQ, Zhao Q, Zhou SL, Mao WM. MSH2 promoter hypermethylation in circulating tumor DNA is a valuable predictor of disease-free survival for patients with esophageal squamous cell carcinoma. Eur J Surg Oncol. 2012;38:326-32.
50. Liu JB, Qiang FL, Dong J, Cai J, Zhou SH, Shi MX, et al. Plasma DNA methylation of Wnt antagonists predicts recurrence of esophageal squamous cell carcinoma. World J Gastroenterol. 2011;17:4917-21.
51. Gyobu K, Yamashita S, Matsuda Y, Igaki H, Niwa T, Oka D, et al. Identification and validation of DNA methylation markers to predict lymph node metastasis of esophageal squamous cell carcinomas. Ann Surg Oncol. 2011;18:1185-94.
52. Huang S, Li XQ, Chen X, Che SM, Chen W, Zhang XZ. Inhibition of microRNA-21 increases radiosensitivity of esophageal cancer cells through phosphatase and tensin homolog deleted on chromosome 10 activation. Dis Esophagus. 2012 (Epub ahead of print).
53. Yang M, Liu R, Sheng J, Liao J, Wang Y, Pan E, et al. Differential expression profiles of microRNAs as potential biomarkers for the early diagnosis of esophageal squamous cell carcinoma. Oncol Rep. 2013;29:169-76.
54. Zhao Y, Schetter AJ, Yang GB, Nguyen G, Mathe EA, Li P, et al. microRNA and inflammatory gene expression as prognostic marker for overall survival in esophageal squamous cell carcinoma. Int J Cancer. 2012 (Epub ahead of print).
55. Komatsu S, Ichikawa D, Takeshita H, Konishi H, Nagata H, Hirajima S, et al. Prognostic impact of circulating miR-21 and miR-375 in plasma of patients with esophageal squamous cell carcinoma. Expert Opin Biol Ther. 2012;12(Suppl 1):S53-9.
56. Kano M, Yamada S, Hoshino I, Murakami K, Akutsu Y, Sakata H, et al. Effects of carbon-ion radiotherapy combined with a novel histone deacetylase inhibitor, cyclic hydroxamic-acid-containing peptide 31 in human esophageal squamous cell carcinoma. Anticancer Res. 2009;29:4433-8.
57. Murakami K, Matsubara H, Hoshino I, Akutsu Y, Miyazawa Y, Matsushita K, et al. CHAP31 induces apoptosis only via the intrinsic pathway in human esophageal cancer cells. Oncology. 2010;78:62-74.
58. Shoji M, Ninomiya I, Makino I, Kinoshita J, Nakamura K, Oyama K, et al. Valproic acid, a histone deacetylase inhibitor, enhances radiosensitivity in esophageal squamous cell carcinoma. Int J Oncol. 2012;40:2140-6.
59. Jones PA, Baylin SB. The epigenomics of cancer. Cell. 2007;128:683-92.
60. Ma X, Ezzeldin HH, Diasio RB. Histone deacetylase inhibitors: current status and overview of recent clinical trials. Drugs. 2009;69:1911-34.